NCT04988997View on ClinicalTrials.gov

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

August 5, 2022

Study Completion Date

August 24, 2022

Conditions
Short Bowel Syndrome
Interventions
DRUG

Vurolenatide 50mg/PBO

Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks

DRUG

Vurolenatide 100mg/PBO

Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks

DRUG

Vurolenatide 50/50 mg

Vurolenatide - 50 mg weekly SC administration

DRUG

Placebo

PBO - weekly SC administration

Trial Locations (6)

27710

Research Site, Durham

30322

Research Site, Atlanta

32610

Research Site, Gainesville

37212

Research Site, Nashville

68198

Research Site, Omaha

02118

Research Site, Boston

Sponsors
All Listed Sponsors
lead

9 Meters Biopharma, Inc.

INDUSTRY

NCT04988997 - VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome. | Biotech Hunter | Biotech Hunter